it is not TGA-approved for human or veterinary therapeutic use
CagriSema requires managing two separate compounds, two reconstitutions, and potentially two injection sites per week
In one embodiment, at least one therapeutic agent is included in a pharmaceutically acceptable enhanced viscosity formulation or composition wherein the formulation or composition further comprises at least one suspending agent, wherein the suspending agent assists in imparting controlled release characteristics to the formulation or composition
Not all compounding pharmacies have the expertise or equipment to produce effective sublingual peptide formulations
[DOI] [PubMed] [Google Scholar] 33.Belosic Halle Z., Vlainic J., Drmic D., Strinic D., Luetic K., Sucic M., Medvidovic-Grubisic M., Pavelic Turudic T., Petrovic I., Seiwerth S., et al